Nektar Therapeutics (NKTR)
37.72
+0.83
(+2.25%)
USD |
NASDAQ |
Oct 15, 16:00
37.73
+0.01
(+0.03%)
After-Hours: 04:11
Nektar Therapeutics Research and Development Expense (Quarterly) : 39.13M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 39.13M |
| March 31, 2026 | 35.68M |
| December 31, 2025 | 29.68M |
| September 30, 2025 | 27.25M |
| June 30, 2025 | 29.89M |
| March 31, 2025 | 30.48M |
| December 31, 2024 | 28.74M |
| September 30, 2024 | 35.03M |
| June 30, 2024 | 29.72M |
| March 31, 2024 | 27.41M |
| December 31, 2023 | 29.94M |
| September 30, 2023 | 24.07M |
| June 30, 2023 | 29.68M |
| March 31, 2023 | 30.47M |
| December 31, 2022 | 34.74M |
| September 30, 2022 | 33.59M |
| June 30, 2022 | 42.74M |
| March 31, 2022 | 107.25M |
| December 31, 2021 | 99.61M |
| September 30, 2021 | 103.74M |
| June 30, 2021 | 101.31M |
| March 31, 2021 | 95.60M |
| December 31, 2020 | 102.72M |
| September 30, 2020 | 100.53M |
| June 30, 2020 | 96.44M |
| Date | Value |
|---|---|
| March 31, 2020 | 108.99M |
| December 31, 2019 | 110.37M |
| September 30, 2019 | 99.05M |
| June 30, 2019 | 106.69M |
| March 31, 2019 | 118.46M |
| December 31, 2018 | 108.88M |
| September 30, 2018 | 102.90M |
| June 30, 2018 | 88.33M |
| March 31, 2018 | 99.42M |
| December 31, 2017 | 81.43M |
| September 30, 2017 | 65.71M |
| June 30, 2017 | 60.26M |
| March 31, 2017 | 61.06M |
| December 31, 2016 | 50.23M |
| September 30, 2016 | 51.95M |
| June 30, 2016 | 52.35M |
| March 31, 2016 | 49.27M |
| December 31, 2015 | 47.14M |
| September 30, 2015 | 43.23M |
| June 30, 2015 | 45.41M |
| March 31, 2015 | 47.01M |
| December 31, 2014 | 38.49M |
| September 30, 2014 | 34.20M |
| June 30, 2014 | 36.70M |
| March 31, 2014 | 38.34M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.819B |
| Inovio Pharmaceuticals, Inc. | 10.50M |
| Tonix Pharmaceuticals Holding Corp. | 19.42M |
| Capricor Therapeutics, Inc. | 28.57M |
| Kyntra Bio, Inc. | 6.821M |